Centaurus: inhibiting ceramide synthesis for cardiometabolic disease

Centaurus is developing DEGS1 inhibitors to block lipotoxicity in cardiometabolic diseases

Centaurus is aiming for first-in-class small molecules that block the lipotoxicity driving cardiometabolic diseases.

Stress stimuli such as inflammation increase production of the structural lipid ceramide, which induces apoptosis, necroptosis and cellular metabolism defects.

Centaurus Therapeutics Inc.’s compounds inhibit DEGS1, an enzyme that converts dihydroceramide into ceramide, for NASH, dyslipidemia, Type II diabetes and other cardiometabolic diseases.

According to co-founder Scott Summers, the Mayo Clinic and hospitals in Europe are

Read the full 688 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers